Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2020 - 2022)

Atea Pharmaceuticals has reported Total Non-Current Liabilities over the past 3 years, most recently at $18.2 million for Q3 2022.

  • Quarterly results put Total Non-Current Liabilities at $18.2 million for Q3 2022, changed N/A from a year ago — trailing twelve months through Sep 2022 was $18.2 million (changed N/A YoY), and the annual figure for FY2021 was $56.9 million, down 81.99%.
  • Total Non-Current Liabilities for Q3 2022 was $18.2 million at Atea Pharmaceuticals, down from $27.9 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AVIR hit a ceiling of $315.8 million in Q4 2020 and a floor of $10.8 million in Q3 2020.
  • Median Total Non-Current Liabilities over the past 3 years was $44.1 million (2021), compared with a mean of $123.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 81.99% in 2021 and later plummeted 89.81% in 2022.
  • Atea Pharmaceuticals' Total Non-Current Liabilities stood at $315.8 million in 2020, then crashed by 81.99% to $56.9 million in 2021, then plummeted by 67.97% to $18.2 million in 2022.
  • The last three reported values for Total Non-Current Liabilities were $18.2 million (Q3 2022), $27.9 million (Q2 2022), and $31.4 million (Q1 2022) per Business Quant data.